Extracellular NM23 Protein as a Therapeutic Target for Hematologic Malignancies
Figure 2
Clinical significance of extracellular NM23-H1 protein in hematologic malignancies. (a) Serum NM23-H1 protein levels in normal healthy control and hematologic malignancies [31]. Normal control (), AML (), ALL (), CML-CP (), CML-BC (), and MDS (), MDS overt leukemia (). Mann-Whitney’s U test versus control, **. (b) Overall survival curves of patients with AML [32]. High-NM23-H1 (≥80 ng/mL) patients () had a worse prognosis than low-NM23-H1(<80 ng/mL) patients (). (c) Overall survival curves of patients with intermediate and high-grade non-Hodgkin’s lymphoma [11, 25]. High-NM23-H1 (>80 ng/mL) patients () had a worse prognosis than low-NM23-H1(<80 ng/mL) patients ().
